<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960306</url>
  </required_header>
  <id_info>
    <org_study_id>30700-5/2021/EÜIG</org_study_id>
    <nct_id>NCT04960306</nct_id>
  </id_info>
  <brief_title>Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection</brief_title>
  <acronym>FILTRATE</acronym>
  <official_title>Fecal Filtrate Versus Conventional Microbiota Transplantation in the Treatment of Multiple Recurrent Clostridioides Difficile Infection (FILTRATE): A Protocol of a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clostridioides difficile infection (CDI) is one of the most common hospital-acquired&#xD;
      infectious diseases with a high mortality rate (6-30%). The treatment of CDI, especially the&#xD;
      recurrent form of the disease is still considered a challenge. The FILTRATE randomized&#xD;
      controlled trial aims to investigate the safety and efficacy of fecal filtrate&#xD;
      transplantation in the treatment of recurrent CDI and compare it with conventional fecal&#xD;
      microbiota transplantation (FMT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of recurrent CDI is still a burden on the healthcare system. FMT is highly&#xD;
      effective for the treatment of recurrent CDI, resulting in the resolution of CDI up to 100%&#xD;
      of the cases. FMT also has a good short-term safety profile, however long-term events like&#xD;
      transfer of multiresistant bacteria and other living microorganism is still a major problem.&#xD;
      On the other hand, the fecal filtrate contains only bacterial debris, proteins, and&#xD;
      antimicrobial compounds and not intact microorganisms.&#xD;
&#xD;
      The FILTRATE trial is a multicenter, two-arm randomized controlled trial, and aims to compare&#xD;
      the safety and efficacy of fecal filtrate transplantation to conventional fecal microbiota&#xD;
      transplantation (FMT) in the treatment of recurrent CDI. Adult patients with multiple&#xD;
      recurrent (&gt;1) CDIs will be randomized 1:1 to receive either FMT or fecal filtrate&#xD;
      transplantation. The transplantation will be carried out using lyophilized capsule on each&#xD;
      arm. The primary endpoint of the study will be the clinical resolution of CDI-associated&#xD;
      diarrhea 8 weeks after the interventions. Questionnaires will be completed on enrollment and&#xD;
      at the time of each follow-up. Adverse events will be recorded and reported to the relevant&#xD;
      institutional and national ethics committee. After the intervention, a one-year follow-up is&#xD;
      also planned. Blood and stool samples will be collected at baseline and at each follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of diarrhea</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical resolution of the CDI associated diarrhea, defined by 2 or less stools (Bristol 1-4) per day in two consecutive days. The rate of the outcome will be compared within groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of diarrhea</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical resolution of the CDI associated diarrhea, defined by 2 or less stools (Bristol 1-4) per day in two consecutive days. The rate of the outcome will be compared within groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of CDI symptoms</measure>
    <time_frame>8 weeks, 1 year</time_frame>
    <description>Recurrence of the CDI symptoms (diarrhea, abdominal pain ect.) within 8 weeks after an initial amelioration. The rate of the outcome will be compared within groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>8 weeks, 1 year</time_frame>
    <description>Overall mortality. The rate of the outcome will be compared within groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease associated mortality</measure>
    <time_frame>8 weeks, 1 year</time_frame>
    <description>Disease-associated mortality. The rate of the outcome will be compared within groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 weeks, 1 year</time_frame>
    <description>Proportion of adverse events (AE) and serious adverse events (SAE). The rate of the outcome will be compared within groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the intestinal microbiome</measure>
    <time_frame>8 weeks, 1 year</time_frame>
    <description>Change of the intestinal microbiome at the end of the follow up period regarding to the initial intestinal microbiome. The rate of the outcome will be compared within groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Recurrent Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Fecal filtrate transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the fecal filtrate transplantation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the conventional fecal microbiota transplantation group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal filtrate transplantation</intervention_name>
    <description>Patients will receive 5-8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size &quot;0&quot; capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules.</description>
    <arm_group_label>Fecal filtrate transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conventional fecal microbiota transplantation</intervention_name>
    <description>Patients will receive 5-8 encapsulated lyophilized conventional fecal microbiota transplantations in enterosolvent, size &quot;0&quot; capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules.</description>
    <arm_group_label>Conventional fecal microbiota transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥18 years&#xD;
&#xD;
          -  multiple recurrent CDI (≥2 previous episodes of CDI)&#xD;
&#xD;
          -  at least 3 or more loose or watery stools (Bristol 5-7) per day&#xD;
&#xD;
          -  a positive Glutamate Dehydrogenase (GDH)-enzyme and positive CDI toxin A and/or B test&#xD;
&#xD;
          -  the patient or the legal guardian sign the written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  ongoing antibiotic treatment&#xD;
&#xD;
          -  fulminant CDI&#xD;
&#xD;
          -  previous FMT&#xD;
&#xD;
          -  immunodeficiency&#xD;
&#xD;
          -  need of intensive care&#xD;
&#xD;
          -  requirement for vasoactive drugs&#xD;
&#xD;
          -  other cause of diarrhea&#xD;
&#xD;
          -  inflammatory bowel diseases&#xD;
&#xD;
          -  irritable bowel syndrome&#xD;
&#xD;
          -  life expectancy shorter than 3 months&#xD;
&#xD;
          -  unavailable for follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Péter Hegyi, MD,PhD, Dsc</last_name>
    <phone>+3672/536-246</phone>
    <email>p.hegyi@tm-centre.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Translational Medicine, University of Pécs</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <contact>
      <last_name>Péter Hegyi, MD,PhD, Dsc</last_name>
      <email>p.hegyi@tm-centre.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>https://tm-centre.org/en/trials/</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Varga A, Kocsis B, Sipos D, Kása P, Vigvári S, Pál S, Dembrovszky F, Farkas K, Péterfi Z. How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods. Front Cell Infect Microbiol. 2021 Jun 4;11:657320. doi: 10.3389/fcimb.2021.657320. eCollection 2021.</citation>
    <PMID>34150673</PMID>
  </results_reference>
  <results_reference>
    <citation>Dembrovszky F, Gede N, Szakács Z, Hegyi P, Kiss S, Farkas N, Molnár Z, Imrei M, Dohos D, Péterfi Z. Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis. Infect Dis Ther. 2021 Mar;10(1):201-211. doi: 10.1007/s40121-020-00356-9. Epub 2020 Oct 26.</citation>
    <PMID>33106983</PMID>
  </results_reference>
  <results_reference>
    <citation>Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, Hohmann EL. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014 Jun;58(11):1515-22. doi: 10.1093/cid/ciu135. Epub 2014 Apr 23.</citation>
    <PMID>24762631</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 10, 2021</last_update_submitted>
  <last_update_submitted_qc>July 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pecs</investigator_affiliation>
    <investigator_full_name>Dr Hegyi Péter</investigator_full_name>
    <investigator_title>Principal Investigator, Director of the Centre for Translational Medicine at University of Pécs</investigator_title>
  </responsible_party>
  <keyword>fecal microbiota transplantation</keyword>
  <keyword>fecal filtrate</keyword>
  <keyword>recurrent infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

